年轻女性接种COVID-19疫苗后月经量过多及其他月经紊乱
在挪威奥斯陆18-30岁女性(n=3972)中采用自对照病例系列设计,比较接种COVID-19疫苗前后月经紊乱风险。首次接种后月经量较平常增多RR为1.90(95%CI 1.69-2.13),第二剂后RR为1.84(95%CI 1.66-2.03),经期延长、月经间隔缩短及经期疼痛加重风险亦升高,且不因疫苗品牌、避孕/激素使用或妇科疾病状态而异。
要点
- 首次接种前末次月经周期中任何月经紊乱的患病率为36.7%。
- 首次接种后月经量较平常增多RR为1.90(95%CI 1.69-2.13),第二剂后RR为1.84(95%CI 1.66-2.03)。
- 两剂接种后经期延长、月经间隔缩短及经期疼痛加重风险亦升高。
核心结论
- 无论是否接种疫苗,月经紊乱均常见。
- 接种疫苗后发现月经紊乱风险升高,尤其是月经量较平常增多、经期延长、月经间隔缩短和经期疼痛加重。
- 未来疫苗试验应纳入月经特征。
研究设计与样本
- 采用电子问卷收集3972名18-30岁参与基于人群的挪威年轻成人队列的女性月经紊乱报告。
- 采用自对照病例系列设计估计接种疫苗后的相对风险(RR)。
- 按疫苗品牌、避孕/激素使用及妇科疾病存在情况进行分层分析。
主要发现
- 首次接种前末次月经周期中任何月经紊乱的患病率为36.7%。
- 首次接种后月经量较平常增多RR为1.90(95%CI 1.69-2.13),第二剂后RR为1.84(95%CI 1.66-2.03)。
- 两剂接种后经期延长、月经间隔缩短及经期疼痛加重风险亦升高。
- 各月经紊乱的RR不因疫苗品牌、避孕/激素使用或妇科疾病存在情况而异。
关键数值与推荐
- 首次接种后月经量较平常增多RR为1.90(95%CI 1.69-2.13)。
- 第二剂接种后月经量较平常增多RR为1.84(95%CI 1.66-2.03)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many signals of menstrual disturbances as possible side effects of vaccination against COVID-19 have been reported. Our objective was to compare the risk of menstrual disturbances before and after vaccination among women aged 18-30 years in Oslo, Norway. METHODS: We used electronic questionnaires to collect reports of menstrual disturbances from 3972 women aged 18-30 years, participating in the population-based Norwegian Young Adult Cohort. We examined the occurrence of menstrual disturbances (heavier bleeding than usual, prolonged bleeding, shorter interval between menstruations, longer interval between menstruations, spot bleedings, stronger pain during menstruation, period pain without bleeding) before and after the first and second dose of COVID-19 vaccine. Relative risks (RR) according to vaccination were estimated using a self-controlled case-series design. We performed additional analyses stratified by vaccine brand, contraception/hormone use, and presence of gynecological condition(s). RESULTS: The prevalence of any menstrual disturbance was 36.7 % in the last menstrual cycle prior the first vaccine dose. The RR for heavier bleeding than usual was 1.90 (95 % CI: 1.69-2.13) after the first vaccine dose and 1.84 (95 % CI 1.66-2.03) after the second dose. Increased risks of prolonged bleeding, shorter interval between menstruations, and stronger pain during menstruation were also observed after both doses. The RRs did not differ with vaccine brand, contraception/hormone use, or presence of gynecological condition(s) for any of the menstrual disturbances. CONCLUSION: Menstrual disturbances were common regardless of vaccination. We found increased risk of menstrual disturbances after vaccination, particularly for heavier bleeding than usual, prolonged bleeding, shorter interval between menstruations, and stronger period pain. In the future, menstrual characteristics should be included in vaccine trials.
引用
- Trogstad L, Laake I, Robertson AH, et al. Heavy bleeding and other menstrual disturbances in young women after COVID-19 vaccination. Vaccine. 2023. PMID: 37451876. doi:10.1016/j.vaccine.2023.06.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。